Shape Therapeutics

NEWS
After its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list, Astellas dismissed its Inflation Reduction Act lawsuit this week, while Illumina got new leadership.
To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
The amount is intended to support the company’s growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
AWARDS
  • NextGen Class of 2021
IN THE PRESS
Shape Therapeutics Inc. presented data at the 27th American Society for Gene and Cell Therapy Annual Meeting in Baltimore, MD showcasing the high therapeutic potential of its RNAfix platform in for the treatment of central nervous system disorders.
Shape Therapeutics Inc., a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer.
Shape Therapeutics today announced its upcoming oral presentations at the 27th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 7-11 in Baltimore, MD.
Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM platforms will be presented at the 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 16-19, 2022 in Washington, D.C.
Shape Therapeutics Inc. will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
Shape Therapeutics Inc. (ShapeTX), today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX.
Shape Therapeutics Inc. today announced a multi-target strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).
Shape Therapeutics Inc. today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital.
Shape Therapeutics Inc., a biotechnology company developing breakthrough technologies to enable gene therapy for all, announced that Francois Vignealt, PhD, President and Chief Executive Officer, is scheduled to present virtually at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00 p.m. Eastern Time.